Key Points – KETAFREE moved closer to a potential summer 2026 approval after the FDA issued mostly minor review comments, and NRx said it has already begun commercial manufacturing at scale.
Management believes the product could serve both hospital and ketamine clinic markets, where supply shortages persist. – NRx said it plans to file an NDA for NRX-100 in Q2, supported by trial data from more than 1,000 patients and real-world evidence from over 65,000 patients
The FDA also indicated it may consider approval based on existing data and broader depression indications, with priority review pathways available. – The company reported a smaller Q1 net loss of about $1.4 million versus $5.5 million a year earlier, and said it ended the quarter with $6.7 million in cash. NRx also said it raised about $7 million after quarter-end and expects current resources to support operations through at least 2026. – 5 Biotech stocks tapping into unmet mental health treatment needs NRx Pharmaceuticals (NASDAQ:NRXP) said it advanced several regulatory, manufacturing and clinical initiatives during the first quarter of 2026, including progress toward potential approval of its preservative-free ketamine product, KETAFREE, and preparations for an NDA filing for NRX-100. Founder, Chairman and Chief Executive Officer Dr.
Jonathan Javitt said the quarter was “productive” and contrasted the company’s current position with a year earlier, when he said NRx had not yet filed for its first drug approval and had $8.7 million in debt. Javitt said the company is now debt free, has sufficient cash for immediate operating needs and raised $7 million after the end of the quarter. KETAFREE Advances Toward Potential Summer 2026 Approval – Doing Your Holiday Shopping?